SCHEMBL7090153

SCHEMBL7090153

O=[N+]([O-])c1cccc2cc(Cl)[nH]c12

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APEX1 P27695 2/20 0.62
PLCG2 P16885 2/20 0.56
MAPT P10636 6/20 0.51
TDP1 Q9NUW8 4/20 0.51
THRB P10828 2/20 0.51
TSHR P16473 2/20 0.51
KDM4E B2RXH2 1/20 0.51
MEN1 O00255 1/20 0.51
CYP1A2 P05177 1/20 0.51
CYP3A4 P08684 1/20 0.51
HPGD P15428 1/20 0.51
NOS3 P29474 1/20 0.51
NOS1 P29475 1/20 0.51
CYP2C19 P33261 1/20 0.51
NOS2 P35228 1/20 0.51
RECQL P46063 1/20 0.51
BLM P54132 1/20 0.51
KMT2A Q03164 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
NPSR1 Q6W5P4 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28592519 0.82 APEX1 (0.62) APEX1PLCG2MAPTTDP1THRB
SCHEMBL28798246 0.82 APEX1 (0.62) APEX1PLCG2MAPTTDP1THRB
SCHEMBL6196504 0.81 APEX1 (0.60) APEX1PLCG2MAPTTDP1THRB
SCHEMBL28311021 0.80 APEX1 (0.56) APEX1PLCG2MAPTTDP1THRB
SCHEMBL27942207 0.78 APEX1 (0.57) APEX1PLCG2MAPTTDP1THRB
SCHEMBL1277212 0.77 APEX1 (1.00) APEX1PLCG2MAPTTDP1THRB
SCHEMBL16380971 0.77 APEX1 (0.56) APEX1PLCG2MAPTTDP1THRB
SCHEMBL5268675 0.77 APEX1 (1.00) APEX1PLCG2MAPTTDP1THRB
SCHEMBL15829263 0.77 APEX1 (0.56) APEX1PLCG2MAPTTDP1THRB
SCHEMBL29288311 0.77 APEX1 (0.60) APEX1PLCG2MAPTTDP1THRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6544981-B2 Anticoagulants, cardiovascular disorders BRISTOL-MYERS SQUIBB COMPANY 2003-04-08 US disclosed
EP-1294716-A1 LACTAM INHIBITORS OF FACTOR XA AND METHOD Bristol-Myers Squibb Company (US) 2003-03-26 EP disclosed
US-20020025957-A1 Lactam inhibitors of factor Xa and method BRISTOL-MYERS SQUIBB COMPANY 2002-02-28 US disclosed
WO-2001096331-A1 LACTAM INHIBITORS OF FACTOR XA AND METHOD BRISTOL-MYERS SQUIBB COMPANY (US) 2001-12-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020025957-A1 Lactam inhibitors of factor Xa and method F9, F7, F11 APEX1 1727/4885PLCG2 1891/4885MAPT 4824/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.